SOLIGENIX, INC. Gain (Loss) on Extinguishment of Debt
SOLIGENIX, INC. (SNGX) reported Gain (Loss) on Extinguishment of Debt of $58.44 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2026-08-07
- SOLIGENIX, INC. gain (loss) on extinguishment of debt for the quarter ending 2026-06-30 was $58.44K.
- SOLIGENIX, INC. gain (loss) on extinguishment of debt for the quarter ending 2023-12-31 was $0.00.
- SOLIGENIX, INC. gain (loss) on extinguishment of debt for the quarter ending 2023-09-30 was $0.00.
- SOLIGENIX, INC. gain (loss) on extinguishment of debt for the quarter ending 2023-06-30 was -$393.79K.
- SOLIGENIX, INC. gain (loss) on extinguishment of debt for fiscal 2023 was -$393.79K.
- SOLIGENIX, INC. gain (loss) on extinguishment of debt for fiscal 2021 was $421.58K.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $58.44K 10-Q · filed 2026-08-07 | $58.44K 10-Q · filed 2026-08-07 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $0.00 derived: sum of 2 quarters · filed 2025-03-21 | -$393.79K derived: sum of 3 quarters · filed 2025-03-21 | -$393.79K 10-K · filed 2025-03-21 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | -$393.79K derived: sum of 2 quarters · filed 2024-11-08 | -$393.79K 10-Q · filed 2024-11-08 | |
| 2023-06-30 | -$393.79K 10-Q · filed 2024-08-09 | -$393.79K 10-Q · filed 2024-08-09 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $0.00 derived: sum of 2 quarters · filed 2023-03-31 | $421.58K derived: sum of 3 quarters · filed 2023-03-31 | $421.58K 10-K · filed 2023-03-31 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $421.58K derived: sum of 2 quarters · filed 2022-11-10 | $421.58K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $421.58K 10-Q · filed 2022-08-12 | $421.58K 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |